Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moFOSCARNET SODIUM (foscarnet sodium) by Gland Pharma is clinical pharmacology pharmacokinetics the pharmacokinetics of foscarnet has been determined after administration as an intermittent intravenous infusion during induction therapy in aids patients with cmv retinitis. Approved for cmv retinitis in patients with acquired immunodeficiency syndrome (aids), acyclovir-resistant mucocutaneous hsv infections in immunocompromised patients. First approved in 2021.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Pharmacokinetics The pharmacokinetics of foscarnet has been determined after administration as an intermittent intravenous infusion during induction therapy in AIDS patients with CMV retinitis. Observed plasma foscarnet concentrations in four studies (FOS-01, ACTG-015, FP48PK,…
Worked on FOSCARNET SODIUM at Gland Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo